UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/450/0.1/15.01.25

UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/450/0.1/15.01.25 Stock

DE000HC49Q12

Real-time BOERSE MUENCHEN 11:41:26 2024-06-26 EDT
5.57 ^EUR	+2.20%

Current month	+15.71%
1 month	+14.02%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/450/0.1/15.01.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating	06-25	MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $555 From $540	06-24	MT
Vertex Pharmaceuticals Discloses 'Positive' Data From Phase 1/2 Trial of VX-880 to Treat Type 1 Diabetes	06-21	MT
Vertex Announces Positive Results From Ongoing Phase 1/2 Study of VX-880 for the Treatment of Type 1 Diabetes Presented at the American Diabetes Association 84th Scientific Sessions	06-21	BU

More news

Quotes 5-day view

Date	Price	Change
24-06-26	5.57	+2.20%
24-06-25	5.45	-3.54%
24-06-24	5.65	+6.60%
24-06-21	5.3	-2.93%
24-06-20	5.46	+3.61%

Real-time BOERSE MUENCHEN

Last update June 26, 2024 at 11:41 am

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	UniCredit
WKN	HC49Q1
ISIN	DE000HC49Q12
Date issued	2023-02-20
Strike	450 $
Maturity	2025-01-15 (203 Days)
Parity	10 : 1
Emission price	1.76 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	6.55 €
Lowest since issue	1.36 €
Delta	0.7x
Omega	5.500
Premium	7.24x
Gearing	7.85x
Moneyness	1.058
Difference Strike	-25.48 $
Difference Strike %	-5.66%
Spread	0.04 €
Spread %	0.70%
Theoretical value	5.630
Implied Volatility	27.64 %
Total Loss Probability	37.70 %
Intrinsic value	2.383
Present value	3.247
Break even	510.16 €
Theta	-0.08x
Vega	0.12x
Rho	0.14x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

473.8 USD

Average target price

465.5 USD

Spread / Average Target

-1.75%

Consensus